NCT04508400: Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients |
|
|
| Completed | 2 | 108 | RoW | Fosaprepitant,ondansetron, dexamethasone, ondansetron, dexamethasone, placebo ondansetron with dexamethasone | Sun Yat-sen University | Pediatric Cancer | 06/23 | 06/23 | | |
ChiCTR2000035363: Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients with solid tumors receiving moderately and highly emetogenic chemotherapy: a multi-center, randomised, double-blind, parallel control phase II randomized trial. |
|
|
| Not yet recruiting | 2 | 108 | | fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients with solid tumors receiving moderately and highly emetogenic chemotherapy ;lacebo plus ondansetron with dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) with MEC/HE multi-day chemotherapy | Sun Yat-sen University Cancer center; Level of the institution：, Jiangsu Chia Tai-Tianqing Pharmaceutical co., Ltd | pediatric solid tumors | | | | |
